Sarah Anderson, oncology strategy lead director, Novotech, discusses the growing prominence of triple-negative breast cancer ...

Sarah Anderson, oncology strategy lead director, Novotech, discusses the significance of triple-negative breast cancer ...

A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...

Triple negative breast cancer wreaks a particularly heavy toll in certain regions and populations, with stark differences in both incidence and survival rates ...

Triple-negative breast cancer (TNBC) has long been one of the most difficult forms of breast cancer to treat. Unlike other breast cancer subtypes, TNBC lacks estrogen, progesterone, and HER2 ...

researchers have developed a method to assess which patients with metastatic triple-negative breast cancer could benefit from ... Oct. 22, 2024 — Researchers evaluated tissues for fibrosis using ...

While triple-negative breast cancer may be more aggressive than hormone receptor-positive breast cancer, it may also be more curable. Family history is a risk factor for breast cancer. A number of ...

Women living with metastatic triple negative breast cancer have new treatment options. Researchers announced last week that Trodelvy (sacituzumab govitecan) significantly prolonged life and ...

Jennifer Griffin was diagnosed with stage 3 triple-negative breast cancer in 2009, and underwent chemotherapy, a double mastectomy, and radiation for treatment. She was declared in remission in 2010.

Izalontamab is under clinical development by Systimmune and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer ...